



Cite this: *Org. Biomol. Chem.*, 2016, **14**, 11220

Synthetic analogs of stryphnusin isolated from the marine sponge *Stryphnus fortis* inhibit acetylcholinesterase with no effect on muscle function or neuromuscular transmission†

Lindon W. K. Moodie,^{‡a} Monika C. Žužek,^b Robert Frangež,^b Jeanette H. Andersen,^c Espen Hansen,^c Elisabeth K. Olsen,^c Marija Cergolj,^{d,e} Kristina Sepčič,^d Kine Ø. Hansen^{*c} and Johan Svenson^{*a,f}

The marine secondary metabolite stryphnusin (**1**) was isolated from the boreal sponge *Stryphnus fortis*, collected off the Norwegian coast. Given its resemblance to other natural acetylcholinesterase antagonists, it was evaluated against electric eel acetylcholinesterase and displayed inhibitory activity. A library of twelve synthetic phenethylamine analogs, **2a–7a** and **2b–7b**, containing tertiary and quaternary amines respectively were synthesized to investigate the individual structural contributions to the activity. Compound **7b** was the strongest competitive inhibitor of both acetylcholinesterase and butyrylcholinesterase with IC₅₀ values of 57 and 20 μM, respectively. This inhibitory activity is one order of magnitude higher than the positive control physostigmine, and is comparable with several other marine acetylcholinesterase inhibitors. The physiological effect of compound **7b** on muscle function and neuromuscular transmission was studied and revealed a selective mode of action at the investigated concentration. This data is of importance as the interference of therapeutic acetylcholinesterase inhibitors with neuromuscular transmission can be problematic and lead to unwanted side effects. The current findings also provide additional insights into the structure–activity relationship of both natural and synthetic acetylcholinesterase inhibitors.

Received 29th September 2016,
Accepted 9th November 2016

DOI: 10.1039/c6ob02120d

www.rsc.org/obc

Introduction

The diverse molecular scaffolds displayed by natural products hold great promise for drug development and have already inspired a number of clinically used drugs.^{1,2} Historically, most compounds have been isolated from terrestrial sources but, as a result of technological advancements, the last 50

years have seen a rise in the number of isolated marine natural products, with some 25 000 reported in the scientific literature.^{2,3} Approximately 500 new marine natural products are reported each year.⁴ To date, the Food and Drug Administration (FDA) has approved seven drugs of marine origin which illustrates their potential.⁵ Natural products generally expand into a broader chemical realm than the synthetic libraries screened by the pharmaceutical industry⁶ and screening success has been shown to increase when including natural-product-like scaffolds.⁷

Nearly half of the new marine natural products reported are isolated from the *Porifera* (sponges) taxon which is attributed to a high content of both opportunistic and symbiotic microorganisms.^{4,8–10} Marine microorganisms are the source of many highly potent natural products which include approved drugs and compounds in clinical trials.^{1,5} The marine microbes are particularly challenging to cultivate and therefore the collection of larger marine benthic organisms remains highly warranted for the continued discovery of novel compounds of microbial origin.

Our recent studies of Arctic marine organisms have led to the characterization of a range of acetylcholinesterase (AChE)

^aDepartment of Chemistry, UiT The Arctic University of Norway, Breivika, N-9037, Tromsø, Norway. E-mail: kine.o.hanssen@uit.no, johan.svenson@sp.se

^bInstitute of Preclinical Sciences, Veterinary faculty, University of Ljubljana, Ljubljana, Slovenia

^cMarbio, UiT The Arctic University of Norway, Breivika, N-9037, Tromsø, Norway

^dDepartment of Biology, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia

^eDepartment of Biotechnology, University of Rijeka, Rijeka, Croatia

^fDepartment of Chemistry, Materials and Surfaces SP Technical Research Institute of Sweden, Box 857, SE-501 15 Borås, Sweden

†Electronic supplementary information (ESI) available: ¹H and ¹³C NMR spectra for synthetic compounds not previously reported and additional neuromuscular experiments. See DOI: 10.1039/c6ob02120d

‡Present address: Department of Chemistry, University of Umeå, SE-901 87, Umeå, Sweden.




inhibitors.¹¹ During these investigations, we have reported the isolation and AChE-inhibitory properties of the halogenated tyrosine derivatives pulmonarin A and B, isolated from the ascidian *Syonicum pulmonaria*.^{12,13} These small, dibrominated compounds displayed AChE inhibition in the pharmaceutically relevant range ($K_i = 90$ and $20 \mu\text{M}$ respectively) and represent interesting marine hits for further studies.¹³

Four brominated indole derivatives have also recently been isolated from the boreal sponge *Geodia barretti*. A library of 22 synthetic compounds was synthesized in order to establish the structure–activity relationship (SAR) against AChE and the role of indole bromination.¹⁴ The most potent natural compounds from that study were the 2,5-diketopiperazines baretin and 8,9-dihydrobaretin which displayed significant inhibition of AChE, (inhibition constants of 29 and $19 \mu\text{M}$ respectively) and butyrylcholinesterase (BChE; inhibition constants of 14 and $48 \mu\text{M}$ respectively) *via* a reversible noncompetitive mechanism.¹⁴

Recent studies also indicate that AChE inhibitor binding to the peripheral anionic site of AChE can be beneficial for the inhibition of the amyloid cascade and offer protection of neural cells against free radical induced damage.²⁴ In addition, patients diagnosed with AD show a progressive increase in the activity of the related cholinesterase enzyme, BChE (E.C. 3.1.1.8). This enzyme is found mainly in the blood plasma,²⁵ and serves as a “back-up” when AChE activity is compromised or absent.²⁶ Both enzymes represent relevant therapeutic targets for ameliorating the symptoms of the AD.

The FDA and European Medicines Agency have approved three compounds addressing the cognitive impairment of AD patients: donepezil, rivastigmine and galanthamine.²¹ The latter two drugs are strongly affiliated with natural products chemistry. Rivastigmine was developed from physostigmine, an alkaloid naturally occurring in the Calabar bean²⁷ while galanthamine was isolated from the bulb of *Galanthus woronowii*.^{28,29} All three compounds inhibit AChE in a reversible



Our previously isolated compounds bear resemblance to other natural AChE inhibitors such as bufotenine, isolated from the mushroom *Amanita mappa*¹⁵ and from a range of frog skin excretions,¹⁶ and deformylflustrabromine originally isolated from the North sea bryozoan *Flustra foliacea*.^{17,18} In addition, similar marine compounds, such as 6-bromohypaphorine has been shown to display agonistic effects on nicotinic acetylcholine receptors¹⁹

The chronic neurodegenerative condition known as Alzheimer's disease (AD) is characterized by progressive degeneration of cholinergic neurons and is the most common cause of dementia.²⁰ AChE (E.C. 3.1.1.7) is the key enzyme for termination of neurotransmission in cholinergic pathways *via* the rapid hydrolysis of the neurotransmitter acetylcholine following its presynaptic release.^{21,22} Therefore, AChE inhibition is a promising approach for symptomatic treatment of AD.²³

manner, and interact directly with the active site or adjacent binding pockets.²¹ Several marine natural products have been shown to display neurological activities although they have yet to reach the market.³⁰ The current state of neurologically active marine natural products was recently reviewed by Sakai and Swanson.³¹

In the present report, we describe the isolation and evaluation of stryphnusin (1), a brominated marine phenethylamine derivative isolated from the Arctic sponge *Stryphnus fortis* (Vosmaer 1885). *S. fortis* is a large, smooth sponge which is found in dense colonies in the northern Atlantic Ocean and is common to the Norwegian coast. *S. fortis* is known for containing the bioactive secondary metabolite ianthelline which displays both antifouling and cytotoxic bioactivities.^{32,33} However, the actual primary producer of ianthelline was recently suggested to be the *Hexadella dedritifera* sponge which com-



monly grows on *S. fortis*.³⁴ No attempts were made to search for *H. dedritifera* in the current *S. fortis* material. The current study represents an extension of our continued search for novel cholinesterase inhibitors of marine origin. Compound **1** is structurally related to the marine AChE inhibitors isolated from *S. pulmonaria* and *G. baretii* and was evaluated for its ability to inhibit AChE. Based on the initial observed inhibitory activity of **1** against electric eel AChE, a library of simpli-

fied synthetic analogs were prepared and evaluated. Although the structure of **1** was originally reported in 2000 after isolation from the Caribbean sponge *Verongula gigantea*,³⁵ and again in 2010, from the Mediterranean phlebobranchiate ascidian *Ciona edwardsii*,³⁶ only limited bioactivity data has been reported. The effect on BChE, and the physiological effect on neuromuscular transmission and muscle function were evaluated for the most active synthetic analog. The data reported expands the knowledge of marine cholinesterase inhibitors and represents the first study of their effect on muscle function.

Table 1 Inhibition of electric eel acetylcholinesterase and horse serum butyrylcholinesterase by natural compounds and their synthetic analogs (**1–7b**)

Compound	IC ₅₀ ^a (μM)	K _i (μM)
AChE		
1	232	235
2a	1675	n.d.
3a	1513	n.d.
4a	1395	n.d.
5a	968	n.d. ^b
6a	774	n.d.
7a	163	202
2b	1096	n.d.
3b	1387	n.d.
4b	1287	n.d.
5b	293	n.d.
6b	444	n.d.
7b	57	51
Physostigmine		
Pulmonarin A ^c	150	90
Pulmonarin B ^c	36	20
6-Bromoconicamin ^c	230	90
Barettin ^c	36	29
BChE		
7b	20	n.d.
6-Bromoconicamin ^c	14	11
Barettin ^c	26	14


^a IC₅₀ is determined as the concentration of the compound inducing 50% inhibition of the enzyme activity. ^b K_i not determined for compounds displaying an IC₅₀ > 250 μM. ^c Data taken from ref. 13 and 14.

Results and discussion

The monobrominated **1** was found in organic phase of the *S. fortis* extract and was isolated using mass guided preparative HPLC. The compound was identified based on spectroscopic analysis.³⁵ Compound **1** was evaluated as inhibitor of electric eel AChE and was found to exhibit a moderate inhibitory activity (Table 1). Based on the initially observed activity, and in order to supplement our previously obtained structure activity relationship (SAR) data, a range of synthetic analogs were prepared and tested, affording six tertiary (**2a–7a**) and six quaternary amines (**2b–7b**) (Scheme 1). The degree and position of phenyl ring bromine, hydroxyl and methoxy substituents was incorporated by consideration of the appropriate phenethylamine starting materials. The tertiary amines **2a–7a** were prepared *via* reductive amination, and further alkylation by methyl iodide yielded the corresponding quaternary amines **2b–7b**. The starting materials for compounds **6a**³⁷ and **7a**³⁸ were prepared using reported methods.

The kinetics of the *in vitro* inhibition of electric eel AChE were assessed by employing the colorimetric assay developed by Ellman³⁹ and the data is presented in Table 1.

The *in vitro* AChE inhibition of **1** was modest with an IC₅₀ of 232 μM (Fig. 1), which is similar to the recently reported



Scheme 1 The synthesis of stryphnusin analogs **2a–7a** and **2b–7b**.






Fig. 1 Inhibition of electric eel acetylcholinesterase (solid symbols) and horse serum butyrylcholinesterase (open symbols) by compounds **1** (triangles) and **7b** (circles). The IC_{50} values towards AChE was determined to be 232 μM for **1** and 57 μM for **7b**, and the IC_{50} value for **7b** towards BChE was determined to be 20 μM .

6-bromoconicamin. The prepared synthetic analogs generally demonstrated weaker inhibition with the exception of **7a** and **7b**, which displayed IC_{50} s of 163 and 57 μM respectively. Compound **7b** was also evaluated as an inhibitor of BChE and displayed an IC_{50} value of 20 μM as shown in Fig. 1.

For those compounds displaying IC_{50} s < 250 μM the inhibitory constants K_i were also determined using Dixon plot analysis, as shown in Fig. 2 for **1** and **7b**. All the examined compounds were shown to be reversible competitive AChE inhibitors, suggesting their binding to the active site of the free enzyme.

Compound **7b** was the most active competitive inhibitor with a K_i of 51 μM in our assays. This was superior to pulmonarin A and 6-bromoconicamin and comparable to pulmonarin B and baretin.^{13,14} When compared to the natural product **1**, it appears that the additional bromination and phenolic methylation are sufficient to increase the inhibitory activity. The reported K_i of the FDA approved AChE inhibitor galanthamine ranges from 2–10 μM (ref. 28) and there is

generally a wide concentration range in which AChE inhibitors effectively exerts their mode of action.⁴⁰ AChE inhibitors also often yield different affinities depending on the enzyme source and experimental setup. The positive control in our study, physostigmine displayed an IC_{50} of 3 μM which is relatively high yet comparable to other reported IC_{50} values against electric eel AChE (0.028–6.45 μM).^{41,42} That implies that the inhibitory activities observed for **7b** is near the pharmaceutically relevant concentration range.

While most of the synthetic analogs were not active enough to motivate their detailed K_i analysis, the link between degree of substitution and the inhibitory potency of the compounds was still evident. The quaternary amines also generally displayed a higher inhibitory activity in relation to their tertiary structural counterparts. By dissecting the molecules into individual chemical constituents it was possible to assess both the charged contribution as well as the Connolly solvent excluded volume of the substituted ethylphenyl part of the molecules as presented in Table 2 and Fig. 3.

The correlation between the bulk of the molecules and their inhibitory activity is clear and this trend is also evident when examining the influence of $\log P$ on activity. The quaternary amines generally displayed higher inhibitory activities in comparison to their tertiary amine counterparts. Although all

Table 2 Correlation between hydrophobic volume, amine substitution and the AChE inhibitory activity of compounds **1–7b**

Compound	Solvent excluded volume ^a (\AA^3)	$\log P^a$	IC_{50} tertiary ("a") (μM)	IC_{50} quaternary ("b") (μM)
1	130.2	3.38	n.a.	232
2	104.6	2.94	1675	1096
3	111.2	2.81	1513	1387
4	126.5	2.55	1395	1287
5	141.7	3.64	968	293
6	150.2	4.21	774	444
7	167.6	4.47	163	57

^a Calculated using ChemBio3D Ultra 14.0 disregarding the substituted and ionized nitrogen atom, hence only the contribution from the substituted ethylphenyl moiety.




Fig. 2 Determination of electric eel AChE inhibition type and the inhibition constants (K_i) for **1** (left graph), and **7b** (right graph) by Dixon plot analysis. The concentrations of the substrate acetylthiocholine were 0.125 (●), 0.25 (□), and 0.50 mM (■). K_i towards AChE was determined to be 235 μM for **1** and 51 μM for **7b**.






Fig. 3 Correlation plot illustrating the influence of the hydrophobic volume on the inhibitory effect of the different types of analogs. -x- are the tertiary amines, 2a–7a and --o-- represent the quaternary amines 1, 2b–7b.

molecules of the current study can be regarded as basic in a physiological context, it is obvious that the constant positive charge of the quaternary compounds **1** and **2b–7b** is beneficial. This is not surprising given that this functionality is chemically analogous with the natural substrate of AChE.⁴³ Isolated **1** and its methoxy analogue **5b**, demonstrate similar activities (232 and 293 μM, respectively), suggesting that these compounds do not engage in any crucial hydrogen bond formation with groups within the active site. It is of interest though, that the dibromomethoxy **7b** (57 μM) is significantly more active than its phenolic counterpart **6b** (444 μM). Considering the data as a whole, we propose that compounds containing large, hydrophobic substituents on the phenyl group, in addition to the quaternary amine, display the most effective inhibitory behavior. These findings contrast our recent study of bromotryptamines where no obvious trend between the hydrophobicity and AChE inhibition was seen.¹⁴




Fig. 4 Effects of **7b** on contractions in isolated mouse hemidiaphragm preparation. (A) Representative control tracing. Arrow (MeOH) indicates superfusion of methanol solution in 0.35 v/v% final concentration. (B) 'Positive control' with AChE inhibitor neostigmine (3 μM). (C) **7b** (20 μM). N—denotes nerve evoked muscle contraction; D—denotes directly elicited muscle contraction; Tn—denotes nerve evoked tetanic contraction; Td—denotes directly elicited tetanic contraction; W—wash out.



The cytotoxicity of the compounds was also evaluated employing human MRC-5 fibroblast. None the included compounds displayed any significant toxic effects at concentrations up to 150 μM (data not included). Compound **1** has previously been tested against rat PC 12 cells and shown to display no toxicity at 10 $\mu\text{g mL}^{-1}$.³⁶ The use of AChE inhibitors can have several drawbacks including unwanted muscle contraction and neuromuscular transmission.^{44,45} Given that **7b** was the most potent molecule from our initial studies, an extensive physiological evaluation of its effects on muscle contraction employing isolated mouse hemidiaphragm was conducted.

The effects of **7b** at the concentration which significantly reduced the AChE activity by 20% (20 μM) on both nerve




Fig. 5 The time-course effects of **7b** on indirectly evoked muscle twitch of isolated mouse hemidiaphragm preparation. Each point represents the mean value \pm SEM obtained from 2–3 different nerve muscle preparations. Graphs including the positive control neostigmine can be found in the ESI.†

evoked and directly elicited single twitch and tetanic contractions in isolated mouse hemidiaphragm preparation were studied. AChE inhibition in hippocampus CA1, CA3 and striatum produced by ethanol extract from *Ptychopetalum olacoides* was shown to be 33%, 20% and 17%, respectively, and these levels of inhibition significantly improved cognitive abilities in old rats.⁴⁶ In line with this, we performed the experiments on muscle function and neuromuscular transmission employing a 20 μM concentration. Reversible AChE inhibitor neostigmine methylsulfate (3 μM) (Sigma-Aldrich, USA) was employed as a positive control. At this concentration neostigmine inhibits AChE in mouse diaphragm muscle by 96%.⁴⁷ In the muscle contraction experiment neostigmine induced characteristic facilitation of neuromuscular transmission associated with anticholinesterase treatment followed by a decrease in indirectly elicited muscle twitches. Neostigmine produced the complete block of tetanic contractions evoked by repetitive nerve stimulation. **7b** appeared to have no effect on directly and indirectly evoked muscle twitch amplitude and the amplitude of directly and indirectly evoked tetanic muscle contraction (Fig. 4 and 5). The potential extended effects of **7b** on indirectly evoked muscle twitch amplitude were also investigated by incubating **7b** for 60 min with the mouse hemidiaphragm preparation (Fig. 6). Compound **7b** behaved in a similar fashion to the negative control (methanol) in the time-course study and appeared to have little effect on muscle contraction, an advantageous property for AChE drugs.

Inhibition of AChE in the neuromuscular junction is associated with the inability to sustain a tetanic contraction produced by the repetitive high frequency stimulation of the motor nerve.⁴⁸ The effect of **7b** on the maximal amplitude of nerve evoked tetanic contraction was thus also established. **7b** did not influence the tetanic contractions and tetanic fade was only seen for the positive control neostigmine in our studies (Fig. S11 in ESI†).




Fig. 6 Effects of **7b** on both, nerve evoked (A) and directly elicited tetanic (B) contractions of isolated mouse hemidiaphragm preparation. Note that **7b** (20 μM) have no effect on the amplitude of directly and indirectly evoked tetanic muscle contraction. Graphs including the positive control neostigmine can be found in the ESI.†






Fig. 7 Effects of **7b** on EPPs amplitude and EPPs half decay. Mouse hemidiaphragm preparations were pretreated for 30 min with 2 μM conotoxin GIIB, and all experiments were performed in the presence of 2 μM conotoxin GIIB to record full sized EPPs and to prevent muscle twitches. Each point represents the mean value ± SEM obtained from 8–12 muscle fibers of each from 2–3 different nerve muscle preparations. Evoked neurotransmitter release (A) and EPPs half decay (B) were determined after 30 and 60 min.

Finally the depolarization effect of **7b** on the skeletal muscle end plate potentials (EPPs) was investigated. For the EPPs experiments the mouse hemidiaphragm preparations were pretreated for 30 min with a 2 μM solution of conotoxin GIIB, and all experiments were further performed in the presence of 2 μM conotoxin GIIB to record full sized EPPs and to prevent muscle twitches. Compound **7b** displayed no prominent activity towards the EPPs and induced no changes in evoked neurotransmitter release (A) or EPPs half decay (B) after both 30 and 60 minutes exposure of the neuromuscular preparation to the compound (Fig. 7).

From the neuromuscular data we can conclude that **7b**, our most potent analog of stryphnusin, inhibits AChE without also inflicting unwanted collateral physiological responses in the neuromuscular system. Of the prepared compounds, only compound **7b** was investigated due to its relatively high inhibitory activity and its structural similarity with both natural and synthetic phenethylamine analogs. Intrigued by this selectivity, and to further investigate the generality of these findings, an analogous synthetic compound, a monobrominated tryptamine from our recent study (compound “**9a**” in ref. 14) was also included.¹⁴ The brominated tryptamine behaved in a very similar fashion (see ESI Fig. S8–S13† for comparison with **7b** and neostigmine) in the neuromuscular experiments. This illustrates that both these types of compounds exert their AChE inhibition without side effects on muscular transmission. To the best of our knowledge, this is the first reported neuromuscular investigation of these types of small, halogenated AChE inhibitors. Several natural AChE inhibitors such as the bufotenins and related compounds display a similar size, degree of substitution and distribution of functionalities and these results illustrate that this structural motif can be used to generate small selective reversible AChE inhibitors.

Conclusions

The marine natural product stryphnusin (**1**) was isolated from an organic extract of the marine sponge *S. fortis*. **1** shares structural features with known AChE inhibitors and the natural substrate and was therefore evaluated for inhibitory activity against electric eel AChE, displaying moderate inhibitory properties. In order to identify analogues with greater activity and to develop a pharmacophore model, a library of 12 compounds was synthesized. The majority of the synthetic compounds were less active than the natural product but **7b**, which contained an additional bromine and methyl functionality, displayed inhibitory properties comparable to several other marine AChE inhibitors. SAR analysis of the library highlighted that both phenyl ring substituents contribute to steric bulk and hydrophobicity, and that analogues bearing a quaternary amine improved activity, thus providing new insights into the structure–activity relationship of AChE inhibitors. Our most promising compound, **7b**, and a structurally related tryptamine, were employed in neuromuscular transmission studies and showed no significant effect; a desirable property when developing therapeutic AChE inhibitors.

Experimental

General experimental procedures

The preparatory HPLC system used to isolate **1** consisted of a 600 pump, a 2996 Photodiode Array UV detector, a 3100 Mass Detector, and a 2767 sample manager (Waters, Milford, MA, USA). NMR spectra were acquired on either a Varian VNMRs 600 MHz or a Varian 7000e 400 MHz spectrometer. Carbon resonances were either acquired directly or derived from gHMBC



experiments and the chemical shifts were referenced to the residual solvent peaks. HRMS was recorded on an LTQ Orbitrap XL Hybrid Fourier Transform mass spectrometer from Thermo Scientific and the Thermo Scientific Accela HPLC-LTQ Ion Trap-Orbitrap Discovery system was used to determine accurate mass of the synthetic compounds. Infrared spectra were recorded on an Avatar 320 FT-IR spectrometer from Nicolet. Solvents, reagents and compound **2a** were acquired from commercial sources and used without further purification. The starting materials for compounds **6a**³⁷ and **7a**³⁸ were prepared using reported methods. Spectroscopic data is included for novel compounds, or those lacking characterization in the literature. For the neuromuscular investigation adult male Balb/C mice were used.

Isolation and characterization of **1**

Specimens of *S. fortis* were collected northwest off Spitsbergen (79°33'N, 8°53'E) at 333 m depth using an Agassiz dredge trawl in September 2007. The sample was stored at -23 °C until use. A subsample is kept at the Norwegian National Marine Biobank (Marbank, reference number M10037), UiT The Arctic University of Norway, Tromsø. Frozen sponge material (2.0 kg) was extracted as previously described yielding 34.62 g of organic extract.³³ The organic extract (2 g) was partitioned between *n*-hexane (150 mL) and 90% MeOH (100 mL). The 90% MeOH fraction was dried under vacuum and further purified by mass guided prep-HPLC using a XTerra RP18 HPLC column employing a linear gradient from 5 to 10% acetonitrile in ultra-pure water (both containing 0.1% formic acid) at a flow rate of 6 mL min⁻¹ over 13 min resulting in the isolation of **1**. The structure of **1** was confirmed using MS, 1D and 2D NMR (COSY) spectroscopic techniques and comparison with literature data.³⁵

General procedure for reductive amination

3-Bromo-*N,N*-dimethyl-4-methoxyphenethylamine (5a). A solution of 3-bromo-4-methoxyphenethylamine (137 mg, 0.44 mmol) in methanol (5 mL) was treated with formaldehyde (330 μL, 4.4 mmol, 37% solution in water) and sodium cyanoborohydride (277 mg, 4.4 mmol). The reaction was stirred for 15 hours and then concentrated under reduced pressure. The resulting thick oil was dissolved in ethyl acetate, washed with saturated sodium bicarbonate, water and brine. After drying with sodium sulfate and removal of solvent, the resulting residue was purified by column chromatography (CHCl₃-MeOH) to afford **5a** (50 mg, 44%). IR (neat) ν_{\max} 2941, 2766, 1497, 1254, 1054, 807 cm⁻¹; ¹H NMR (600 MHz, CD₃OD) δ 7.40 (1H, d, *J* = 2.1 Hz), 7.16 (1H, dd, *J* = 8.4, 2.1 Hz), 6.95 (1H, d, *J* = 8.4 Hz), 3.84 (3H, s), 2.74–2.70 (2H, m), 2.57–2.51 (2H, m), 2.31 (6H, s); ¹³C NMR (151 MHz, CD₃OD) δ 155.9, 134.7, 134.3, 129.9, 113.4, 112.4, 62.2, 56.7, 45.3, 33.3; HRMS *m/z* 258.0488 (calcd for C₁₁H₁₇⁷⁹BrNO [M + H]⁺: 258.0489).

The spectral data of compounds **3a** (55%, 0.38 mmol),⁴⁹ **4a** (88%, 0.52 mmol),⁵⁰ and **6a** (73%, 0.1 mmol)⁵¹ were consistent with previous reports.

3,5-Dibromo-*N,N*-dimethyl-4-methoxyphenethylamine (7a). (63%, 0.23 mmol) amorphous solid; IR (neat) ν_{\max} 2926, 1471, 1260, 993, 737 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.35 (2H, s), 3.86 (3H, s), 2.76–2.72 (2H, m), 2.60–2.55 (2H, m), 2.34 (6H, s); ¹³C NMR (151 MHz, CDCl₃) δ 152.6, 132.9, 131.0, 118.1, 60.7, 60.7, 45.3, 29.9; HRMS *m/z* 335.9596 (calcd for C₁₁H₁₆⁷⁹Br₂NO [M + H]⁺: 335.9593).

General procedure for quaternary amine formation

(3-Bromo-4-methoxyphenethyl)trimethylammonium iodide (5b). Compound **5a** (34 mg, 0.13 mmol) was dissolved in methanol (2 mL) and treated with methyl iodide (33 μL, 0.53 mmol). After 12 hours, the reaction was concentrated under reduced pressure, the resulting solid washed with cold methanol, providing the product **5b** (48 mg, 91%) (iodide salt) as an amorphous solid. IR (neat) ν_{\max} 2970, 1498, 1255, 1054, 953 cm⁻¹; ¹H NMR (400 MHz, (CD₃)₂SO) δ 7.59 (1H, d, *J* = 2.2 Hz), 7.31 (1H, dd, *J* = 8.4, 2.2 Hz), 7.10 (1H, d, *J* = 8.4 Hz), 3.83 (3H, s), 3.54–3.45 (2H, m), 3.13 (9H, s), 3.03–2.96 (2H, m); ¹³C NMR (101 MHz, (CD₃)₂SO) δ 154.3, 133.3, 129.8, 129.6, 112.8, 110.6, 65.7, 56.2, 52.3, 27.1; HRMS *m/z* 272.0647 (calcd for C₁₂H₁₉⁷⁹BrNO [M]⁺: 272.0645).

The spectral data of compounds **6b** (82%, 0.04 mmol)⁵² was consistent with those reported. Compounds **2b**,⁵³ **3b**,⁵⁴ **4b**⁵⁵ and **7b**⁵⁶ have been reported but lack full characterization data.

(Phenethyl)trimethylammonium iodide (2b). (84%, 0.57 mmol) amorphous solid; IR (neat) ν_{\max} 1689, 1479, 1201, 1054, 740, 699 cm⁻¹; ¹H NMR (600 MHz, CD₃OD) δ 7.38–7.32 (4H, m), 7.29–7.26 (1H, m), 3.64–3.58 (2H, m), 3.25 (9H, s), 3.18–3.12 (2H, m), ¹³C NMR (151 MHz, CD₃OD) δ 136.9, 130.1, 130.0, 128.4, 68.4*, 53.8*, 30.3; HRMS *m/z* 164.1431 (calcd for C₁₁H₁₈N [M]⁺: 164.1434). *Present as triplets.

(4-Hydroxyphenethyl)trimethylammonium iodide (3b). (88%, 0.08 mmol) amorphous solid; IR (neat) ν_{\max} 3237, 2413, 1608, 1511, 1213, 836 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) δ 7.15 (2H, d, *J* = 8.4 Hz), 6.76 (2H, d, *J* = 8.5 Hz), 3.57–3.49 (2H, m), 3.22 (9H, s), 3.08–2.99 (2H, m); ¹³C NMR (101 MHz, CD₃OD) δ 157.9, 131.1, 127.3, 116.7, 68.8*, 53.7*, 29.5; HRMS *m/z* 180.1383 (calcd for C₁₁H₁₈NO [M]⁺: 180.1383). *Present as triplets.

(4-Methoxyphenethyl)trimethylammonium iodide (4b). (88%, 0.20 mmol) amorphous solid; IR (neat) ν_{\max} 1610, 1513, 1246, 1179, 823 cm⁻¹; ¹H NMR (600 MHz, CD₃OD) δ 7.27 (2H, d, *J* = 8.7 Hz), 6.90 (2H, d, *J* = 8.7 Hz), 3.77 (3H, s), 3.60–3.53 (2H, m), 3.24 (9H, s), 3.11–3.03 (2H, m); ¹³C NMR (151 MHz, CD₃OD) δ 160.4, 131.2, 128.6, 115.4, 68.6*, 55.7, 53.8*, 29.5; HRMS *m/z* 194.1540 (calcd for C₁₂H₂₀NO [M]⁺: 194.1539). *Present as triplets.

(3,5-Dibromo-4-methoxyphenethyl)trimethylammonium iodide (7b). (84%, 0.09 mmol) amorphous solid; IR (neat) ν_{\max} 2928, 1467, 1259, 958, 737 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) δ 7.63 (2H, s), 3.85 (3H, s), 3.60–3.54 (2H, m), 3.22 (9H, s), 3.15–3.07 (2H, m); ¹³C NMR (101 MHz, CD₃OD) δ 154.8, 134.6, 133.6, 119.3, 67.7, 61.1*, 53.8*, 28.8; HRMS *m/z* 349.9762 (calcd for C₁₂H₁₈⁷⁹Br₂NO [M]⁺: 349.9750). *Present as triplets.



Cholinesterase inhibition assay

Cholinesterase activity was measured by Ellman's method, using acetylthiocholine chloride (0.125, 0.25, and 0.5 mM, respectively) as a substrate in 100 mM potassium phosphate buffer pH 7.4 at 25 °C, and electric eel AChE, or horse serum BChE as enzyme sources (Sigma, final concentration in the test 0.0075 U mL⁻¹). Hydrolysis of acetylthiocholine chloride was followed on a VIS microplate reader (Dynex Technologies, USA) at 405 nm. AChE or BChE inhibition was monitored for 5 minutes at 20 °C for each compound (prepared from a 2 mg mL⁻¹ stock in methanol and then progressively diluted in 100 mM potassium phosphate buffer pH 7.4). The positive control (physostigmine, Sigma) was prepared in ethanol (at a 10 mM final concentration) and progressively diluted in the same buffer. The effect of the pure methanol or ethanol on enzyme inhibition was also checked, and all readings were corrected for their appropriate blanks. Every measurement was repeated at least three times.

Cytotoxicity testing

The potential cytotoxicity of compounds 1–7b was evaluated against human MRC-5 normal lung fibroblasts, using the tetrazolium based (MTS) CellTiter 96® Aqueous One Solution Cell Proliferation Assay. Percent cell survival was calculated by comparing exposed cells to untreated cells and cells treated with Triton X-100 (0.01%), as previously described.³³

Muscle contraction experiments

Mice were sacrificed by cervical dislocation, followed by immediate exsanguination. The diaphragm with corresponding phrenic nerves was dissected and used.

Hemidiaphragm was tightly pinned to the Rhodorsil coated organ bath containing oxygenated standard Krebs-Ringer solution composed of (in mM): 154 NaCl, 2 CaCl₂, 5 KCl, 1 MgCl₂, 5 HEPES and 11 D-glucose, pH 7.4, at 22–24 °C. The tendinous side of the hemidiaphragm was attached with a steel hook *via* silk thread to an isometric force displacement transducer FT 03 (Grass instruments, West Warwick, RI, USA). Nerve-evoked single isometric twitches were recorded as follows: the motor nerve of isolated neuromuscular preparation was stimulated with a square pulse S-48 stimulator (Grass instruments, West Warwick, RI, USA) *via* a suction electrode with pulses of 0.1 ms duration, 0.1 Hz stimulation rate and with the supramaximal voltage of 8–10 V. Directly evoked single isometric twitches were evoked by stimulating hemidiaphragm preparation with a platinum electrode assembly placed along the organ bath with pulses of 0.1 ms in duration, with a 0.1 Hz stimulation rate and with the supramaximal voltage of 60–80 V. Directly or nerve-evoked tetanic muscle contraction recordings were obtained by stimulating the hemidiaphragm with train of pulses (1000 ms duration at 80 Hz). Each hemidiaphragm preparation was then left to equilibrate for 20 min to achieve stable resting tension before beginning the experiments. Electrical signals were amplified by a P122 strain gage amplifier (Grass instruments, West Warwick, RI, USA) and then digi-

tized at a sampling rate of 1 kHz using a data acquisition system (Digidata 1440A; Molecular Devices, Sunnyvale, CA, USA).⁵⁷ The effect of 7b on the neuromuscular hemidiaphragm preparation was measured for 60 min.

Recordings of end plate potentials (EPPs)

The experiments were performed at 22–24 °C on oxygenated mouse hemidiaphragm preparations, pretreated for 30 min with 2 μM μ-conotoxin GIIIB, an inhibitor of muscle sodium channels, to record full-sized endplate potentials without contracting the muscle. The resting membrane potentials and endplate potentials (EPPs) were recorded from endplate regions in superficial muscle fibres using intracellular borosilicate microelectrodes filled with 3 M KCl and pulled with a P-97 Flaming/Brown microelectrode puller (Sutter Instruments, Novato, CA, USA). Microelectrodes with resistance from 10–20 MΩ were used. Recordings were performed before, 30 and 60 min after application of 7b, and 15 min after washing-out the 7b. EPPs were evoked by stimulating the phrenic nerve with supramaximal square pulses of 0.1 ms duration and with a frequency of 1 Hz. EPP and MEPP recordings were digitized using Digidata 1440A and the pClamp 10 software. Data were analyzed using the pClamp-Clampfit 10 program. Amplitudes of EPPs were normalized to a membrane potential of –70 mV using the formula $V_c = V_0 \times (-70)/E$, where V_c is the normalized amplitude of EPPs, V_0 is the recorded amplitude and E is the resting membrane potential.

Data analysis and statistics

Data were statistically analysed using SigmaPlot for Windows 11.0 (Systat Software Inc., Germany). The results are presented as the mean ± SEM. Data were firstly tested for normality (Shapiro–Wilk) and equal variance for assignment to parametric or non-parametric analysis. For the statistical analysis of the data, a two-tailed Student *t*-test was used and *P* value ≤0.05 was considered to be statistically significant.

Acknowledgements

This work was partly supported with grants from the Norwegian research council (ES508288) and JS and LM are grateful for the support. The Slovenian authors wish to thank the Slovenian research agency for financial support (Grant P1-0207 and P4-0053), and the ERASMUS Student mobility programme for financial support of MC.

Notes and references

- W. H. Gerwick and B. S. Moore, *Chem. Biol.*, 2012, **19**, 85–98.
- G. M. Cragg and D. J. Newman, *Biochim. Biophys. Acta, Gen. Subj.*, 2013, **1830**, 3670–3695.
- T. F. Molinski, D. S. Dalisay, S. L. Lievens and J. P. Saludes, *Nat. Rev. Drug Discovery*, 2009, **8**, 69–85.



- 4 J. W. Blunt, B. R. Copp, R. A. Keyzers, M. H. Munro and M. R. Prinsep, *Nat. Prod. Rep.*, 2015, **32**, 116–211.
- 5 W. H. Gerwick and A. M. Fenner, *Microb. Ecol.*, 2013, **65**, 800–806.
- 6 A. L. Harvey, R. Edrada-Ebel and R. J. Quinn, *Nat. Rev. Drug Discovery*, 2015, **14**, 111–129.
- 7 J. Hert, J. J. Irwin, C. Laggner, M. J. Keiser and B. K. Shoichet, *Nat. Chem. Biol.*, 2009, **5**, 479–483.
- 8 M. C. Leal, J. Puga, J. Serôdio, N. C. Gomes and R. Calado, *PLoS One*, 2012, **7**, 1–15.
- 9 G. Steinert, S. Whitfield, M. W. Taylor, C. Thoms and P. J. Schupp, *Mar. Biotechnol.*, 2014, **16**, 594–603.
- 10 U. Hentschel, J. Piel, S. M. Degnan and M. W. Taylor, *Nat. Rev. Microbiol.*, 2012, **10**, 641–654.
- 11 J. Svenson, *Phytochem. Rev.*, 2013, **12**, 567–578.
- 12 M. Tadesse, M. B. Strøm, J. Svenson, M. Jaspars, B. F. Milne, V. Tørfoss, J. H. Andersen, E. Hansen, K. Stensvåg and T. Haug, *Org. Lett.*, 2010, **12**, 4752–4755.
- 13 M. Tadesse, J. Svenson, K. Sepčić, L. Trembleau, M. Engqvist, J. H. Andersen, M. Jaspars, K. Stensvåg and T. Haug, *J. Nat. Prod.*, 2014, **77**, 364–369.
- 14 E. K. Olsen, E. Hansen, L. W. K. Moodie, J. Isaksson, K. Sepčić, M. Cergolj, J. Svenson and J. H. Andersen, *Org. Biomol. Chem.*, 2016, **14**, 1629–1640.
- 15 J. Harley-Mason and A. Jackson, *J. Chem. Soc.*, 1954, 1165–1171.
- 16 S. Bhattacharya and A. Sanyal, *Indian J. Physiol. Pharmacol.*, 1971, **15**, 133–134.
- 17 N. Lysek, E. Rachor and T. Lindel, *Z. Naturforsch.*, 2002, **57**, 1056–1061.
- 18 L. Peters, G. M. König, H. Terlau and A. D. Wright, *J. Nat. Prod.*, 2002, **65**, 1633–1637.
- 19 I. E. Kasheverov, I. V. Shelukhina, D. S. Kudryavtsev, T. N. Makarieva, E. N. Spirova, A. G. Guzii, V. A. Stonik and V. I. Tsetlin, *Mar. Drugs*, 2015, **13**, 1255–1266.
- 20 A. V. Terry and J. J. Buccafusco, *J. Pharmacol. Exp. Ther.*, 2003, **306**, 821–827.
- 21 M. B. Colovic, D. Z. Krstic, T. D. Lazarevic-Pasti, A. M. Bondzic and V. M. Vasic, *Curr. Neuropharmacol.*, 2013, **11**, 315–335.
- 22 V. N. Talesa, *Mech. Ageing Dev.*, 2001, **122**, 1961–1969.
- 23 D. Munoz-Torrero, *Curr. Med. Chem.*, 2008, **15**, 2433–2455.
- 24 N. Tabet, *Age Ageing*, 2006, **35**, 336–338.
- 25 L. Pezzementi and A. Chatonnet, *Chem.-Biol. Interact.*, 2010, **187**, 27–33.
- 26 B. Li, J. A. Stribley, A. Ticu, W. Xie, L. M. Schopfer, P. Hammond, S. Brimijoin, S. H. Hinrichs and O. Lockridge, *J. Neurochem.*, 2000, **75**, 1320–1331.
- 27 D. J. Triggle, J. M. Mitchell and J. Filler, *CNS Drug Rev.*, 1998, **4**, 87–136.
- 28 H. Geerts, P. O. Guillaumat, C. Grantham, W. Bode, K. Anciaux and S. Sachak, *Brain Res.*, 2005, **1033**, 186–193.
- 29 M. Heinrich and H. L. Teoh, *J. Ethnopharmacol.*, 2004, **92**, 147–162.
- 30 D. Kudryavtsev, T. Makarieva, N. Utkina, E. Santalova, E. Kryukova, C. Methfessel, V. Tsetlin, V. Stonik and I. Kasheverov, *Mar. Drugs*, 2014, **12**, 1859–1875.
- 31 R. Sakai and G. T. Swanson, *Nat. Prod. Rep.*, 2014, **31**, 273–309.
- 32 K. Ø. Hanssen, G. Cervin, R. Trepos, J. Petitbois, T. Haug, E. Hansen, J. H. Andersen, H. Pavia, C. Hellio and J. Svenson, *Mar. Biotechnol.*, 2014, **16**, 684–694.
- 33 K. Ø. Hanssen, J. H. Andersen, T. Stiberg, R. A. Engh, J. Svenson, A.-M. Genevière and E. Hansen, *Anticancer Res.*, 2012, **32**, 4287–4297.
- 34 P. Cárdenas, *J. Chem. Ecol.*, 2016, **42**, 339–347.
- 35 P. Ciminiello, C. Dell'Aversano, E. Fattorusso, S. Magno and M. Pansini, *J. Nat. Prod.*, 2000, **63**, 263–266.
- 36 A. Aiello, E. Fattorusso, C. Imperatore, M. Menna and W. E. Müller, *Mar. Drugs*, 2010, **8**, 285–291.
- 37 E. García-Egido, J. Paz, B. Iglesias and L. Muñoz, *Org. Biomol. Chem.*, 2009, **7**, 3991–3999.
- 38 R. M. Van Wagoner, J. Jompa, A. Tahir and C. M. Ireland, *J. Nat. Prod.*, 1999, **62**, 794–797.
- 39 G. L. Ellman, K. D. Courtney, V. Andres and R. M. Featherstone, *Biochem. Pharmacol.*, 1961, **7**, 88–95.
- 40 K. Hostettmann, A. Borloz, A. Urbain and A. Marston, *Curr. Org. Chem.*, 2006, **10**, 825–847.
- 41 M. R. Loizzo, R. Tundis, F. Menichini and F. Menichini, *Curr. Med. Chem.*, 2008, **15**, 1209–1228.
- 42 F. Menichini, R. Tundis, M. R. Loizzo, M. Bonesi, M. Marrelli, G. A. Statti, F. Menichini and F. Conforti, *Fitoterapia*, 2009, **80**, 297–300.
- 43 M. Pohanka, *Biomed. Pap.*, 2011, **155**, 219–229.
- 44 J. Morrison, *Br. J. Pharmacol.*, 1977, **60**, 45–53.
- 45 A. L. Clark and F. Hobbiger, *Br. J. Pharmacol.*, 1983, **78**, 239–246.
- 46 M. Figueiró, J. Ilha, D. Pochmann, L. Porciúncula, L. Xavier, M. Achaval, D. Nunes and E. Elisabetsky, *Phytomedicine*, 2010, **17**, 956–962.
- 47 J. Minic, A. Chatonnet, E. Krejci and J. Molgó, *Br. J. Pharmacol.*, 2003, **138**, 177–187.
- 48 C. Chang, S. Hong and J. L. Ko, *Br. J. Pharmacol.*, 1986, **87**, 757–762.
- 49 A. Küçükosmanoğlu Bahçeevli, S. Kurucu, U. Kolak, G. Topçu, E. Adou and D. G. I. Kingston, *J. Nat. Prod.*, 2005, **68**, 956–958.
- 50 M. Saravanan, K. S. Kumar, P. P. Reddy and B. Satyanarayana, *Synth. Commun.*, 2010, **40**, 1880–1886.
- 51 H. Kigoshi, K. Kanematsu, K. Yokota and D. Uemura, *Tetrahedron*, 2000, **56**, 9063–9070.
- 52 X. Fu and F. J. Schmitz, *J. Nat. Prod.*, 1999, **62**, 1072–1073.
- 53 H. Decker and P. Becker, *Ber. Dtsch. Chem. Ges.*, 1912, **45**, 2404–2409.
- 54 G. Barger, *J. Chem. Soc.*, 1909, **95**, 2193–2197.
- 55 K. W. Rosenmund, *Ber. Dtsch. Chem. Ges.*, 1910, **43**, 306–313.
- 56 E. Leete, R. M. Bowman and M. F. Manuel, *Phytochemistry*, 1971, **10**, 3029–3033.
- 57 M. Grandič, R. Aráoz, J. Molgó, T. Turk, K. Sepčić, E. Benoit and R. Frangež, *Toxicol. Appl. Pharmacol.*, 2012, **265**, 221–228.

